https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38251689&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09 382516892024032720240629
2155-384X1532024Mar01Clinical and translational gastroenterologyClin Transl GastroenterolSevelamer-Induced Gastrointestinal Disease in 12 Patients with End-Stage Renal Disease: A Case Series.e00679e00679e0067910.14309/ctg.0000000000000679Isolated case reports and case series have linked the use of sevelamer to severe gastrointestinal (GI) inflammation and perforation among patients with end-stage renal disease.In this study, we identified 12 cases of biopsy-proven sevelamer-induced gastrointestinal disease from a large urban community hospital over the course of 5 years. We described baseline characteristics, sites and types of injury, histological findings, timing and dosing of sevelamer initiation compared with symptom onset, and in a smaller subset, endoscopic resolution post drug cessation. We also reviewed preexisting conditions to identify trends in populations at risk.Several of the patients reviewed had preexisting conditions of decreased motility and/or impaired mucosal integrity. The presentation of disease was broad and included both upper-GI and lower-GI pathologies and in varying severity.There is a broad phenotypic range of sevelamer-induced gastrointestinal disease. As this becomes a more frequently recognized pathology, clinicians should be aware of how it may present and which populations may be more susceptible.Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.ToddJamesJDepartment of Internal Medicine, Carolinas Medical Center at Atrium Health, Charlotte, North Carolina, USA.SabooriShadabSDepartment of Gastroenterology and Hepatology, Carolinas Medical Center at Atrium Health, Charlotte, North Carolina, USA.ZeidanJosephJDepartment of Gastroenterology and Hepatology, Carolinas Medical Center at Atrium Health, Charlotte, North Carolina, USA.AhrensWilliamWDepartment of Pathology, Carolinas Medical Center at Atrium Health, Charlotte, North Carolina, USA.JacobsCarlCDepartment of Pathology, Carolinas Medical Center at Atrium Health, Charlotte, North Carolina, USA.MoshireeBahaBDepartment of Gastroenterology and Hepatology, Carolinas Medical Center at Atrium Health, Charlotte, North Carolina, USA.Wake Forest School of Medicine-Carolinas Campus, Charlotte, North Carolina, USA .engJournal Article20240301
United StatesClin Transl Gastroenterol1015321422155-384X9YCX42I8IUSevelamer0Chelating AgentsIMHumansSevelameradverse effectsChelating Agentsadverse effectsRenal Dialysisadverse effectsKidney Failure, ChronicGastrointestinal Diseaseschemically induceddiagnosisGuarantor of the article: James Todd, DO. Specific author contributions: J.T.: conceptualization, investigation, formal analysis, writing. S.S.: supervision, writing, review and editing. J.Z.: conceptualization, investigation. W.A.: investigation, supervision, review and editing. C.J.: investigation, supervision, review and editing. B.M.: conceptualization, supervision, review and editing. All authors had access to the study data and reviewed and approved the final manuscript. Financial support: None to report. Potential competing interests: None to report.2023919202411020243276432024122124320241228122024122epublish38251689PMC1096289310.14309/ctg.000000000000067901720094-990000000-00227Philpott HL, Nandurkar S, Lubel J, et al. . Drug-induced gastrointestinal disorders. Frontline Gastroenterol 2014;5(1):49–57.PMC536970228839751Navaneethan SD, Palmer SC, Vecchio M, et al. . Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011(2):CD006023.21328279Amer S, Nguyen C, DePetris G. Images of the month: Gastric pneumatosis due to sevelamer-mediated necrosis. Am J Gastroenterol 2015;110(6):799.26052763Tieu C, Moreira RK, Song LMWK, et al. . A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterol 2016;16(1):20.PMC476503526911806Magee J, Robles M, Dunaway P. Sevelamer-induced gastrointestinal injury presenting as gastroenteritis. Case Rep Gastroenterol 2018;12(1):41–5.PMC583620929515344Lai T, Frugoli A, Barrows B, et al. . Sevelamer carbonate crystal-induced colitis. Case Rep Gastrointest Med 2020;2020:4646732.PMC739604432774946Arriola AG, Martin ND, Tondon R. Crystals in perforated bowel: Culprits or innocent bystanders. Int J Surg Pathol 2018;26(3):238–9.28982290George SA, Francis I. Pathology of resin-induced gastrointestinal damage: Report of 15 cases and review of literature. Turkish J Pathol 2019;35(3):221–7.31026044Modi RM, Swanson B, Duggirala V. Long-standing diarrhea associated with sevelamer crystalopathy in colonic mucosa. Clin Gastroenterol Hepatol 2017;15(2):A23-7.27989850Nambiar S, Pillai UK, Devasahayam J, et al. . Colonic mucosal ulceration and gastrointestinal bleeding associated with sevelamer crystal deposition in a patient with end stage renal disease. Case Rep Nephrol 2018;2018:1–3.PMC585116329682371Okwara CJ, Gulati R, Rustagi T, et al. . Upper gastrointestinal bleeding of unusual causation. Dig Dis Sci 2018;63(10):2541–6.30178284Keri KC, Veitla V, Samji NS. Ischemic colitis in association with sevelamer crystals. Indian J Nephrol 2019;29(3):191–3.PMC652177331142966Desai M, Reiprich A, Khov N, et al. . Crystal-associated colitis with ulceration leading to hematochezia and abdominal pain. Case Rep Gastroenterol 2016;10(2):332–7.PMC494580927482192Okwara C, Choi C, Park JY. Sevelamer-induced colitis presenting as a pseudotumor. Clin Gastroenterol Hepatol 2015;13(7):A39–A40.25701702Yang JY, Lee TC, Montez-Rath ME, et al. . Trends in the incidence of intestinal perforation in US dialysis patients (1992–2005). J Nephrol 2013;26(2):281–8.PMC411724522419235Kim T, de Oliveira Silva Lautenschlager S, Ma Q, et al. . Drug crystal-related gastrointestinal complications involve crystal-induced release of neutrophil and monocyte extracellular traps. Cells 2020;9(11):2481.PMC769700833203124Madan P, Bhayana S, Chandra P, et al. . Lower gastrointestinal bleeding: Association with sevelamer use. World J Gastroenterol 2008;14(16):2615–6.PMC270838318442219Qunibi WY, Hootkins RE, McDowell LL, et al. . Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate renagel evaluation (care study). Kidney Int 2004;65(5):1914–26.15086935Phuong-Nguyen K, McNeill BA, Aston-Mourney K, et al. . Advanced glycation end-products and their effects on gut health. Nutrients 2023;15(2):405.PMC986751836678276